Billy McKnight has taken over from Dr Gordon Logan as general manager of Thermo LabSystems' Informatics business. He previously worked for Thermo Electron's analytical instruments division. Kevin Smith was recently appointed to the new post of vice president, Informatics in North America.
Dr Nicholas Pay has been made a non-executive director of Cytomyx, the discovery research organisation. Dr Pay brings extensive experience of business development and general management from leading life sciences companies, including Roche Diagnostics and Becton Dickinson.
Rhodia ChiRex has appointed Dr Tom Archibald as vice president of research and technology. The company has also named three new business development executives: Phillip M. Chalabi and Joseph Kamon, based in the US; and Philippe Tramoy, based in Lyon in France.
Entomed, the French company which develops novel medicines from insects, has nominated two new members to its scientific advisory board: Professor Jean-Claude Braekman, director of the department of organic chemistry at the Universite Libre de Bruxelles; and Dr Luis Serrano, programme co-ordinator structural and computational biology at the European Molecular Biology Laboratory, Germany.
Dutch drug discovery company Kiadis has appointed Dr Steve Long as director of drug discovery. He will oversee in-house drug discovery and development programmes.
Malvern Instruments has appointed Kevin Mattison to the post of applications manager, protein technology. He was previously director of r&d at Protein Solutions in the United States.
Dr John Fell, a senior lecturer at the School of Pharmacy and Pharmaceutical Sciences at the University of Manchester in the UK, has been appointed as a consultant to tablet press manufacturer Manesty. At the university he is involved with the mechanics of solids dosage production and clinical efficacy.
Two senior appointments have been made by AstraZeneca. Dr Martin Nicklasson has been named executive vice president, development, with responsibility for global drug development, and Dr Jan Lundberg is the new executive vice president, discovery research, responsible for all global discovery programmes.